The European Patent Office (EPO) has granted Autonomix Medical Inc. a patent that strengthens its nerve-targeted cardiac tissue therapy prowess.

Patent No. EP4230133 (the ‘133 patent), titled, “Controlled and Precise Treatment of Cardiac Tissues, covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and then deliver therapy with closed-loop feedback to precisely treat cardiac tissues by performing feedback-driven neuromodulation, denervation, and/or tissue ablation.

“This European patent represents another important milestone in strengthening and expanding the global IP foundation behind our breakthrough technology platform,” Autonomix CEO Brad Hauser commented. “This patent builds on and broadens the protection provided by our recently issued U.S. Patent No. 12,369,852, further enhancing our ability to provide precision nerve-targeted therapies that have the potential to transform treatment in key, high-growth areas of cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina, while reducing complications.”

The ‘133 patent particularly relates to systems, devices, and methods for performing precise treatment, mapping, and/or testing of tissues and for identifying, localizing, monitoring, and mapping neural traffic near targeted regions. Further, the patent highlights applications across arrhythmias (atrial and ventricular), ischemia/angina (including refractory angina pain), coronary spasm, myocardial infarction risk modulation, heart failure, hypertension (including interplay with renal-cardiac nerves), and plaque/inflammation modulation, where local, feedback-guided denervation or modulation may reduce dependence on systemic beta blockade and its side effects.

Autonomix’s first-in-class technology constitutes a platform with the potential to address dozens of indications in multiple high-need therapeutic areas, including cardiology and resistant hypertension or high blood pressure, interventional pain management, pulmonary and gastrointestinal disorders, and more.

Autonomix is a medical device company advancing technologies to revolutionize the ways in which diseases involving the nervous system are diagnosed and treated. The company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than currently available technologies. Such technology could enable—for the first time—transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

The company initially is developing this technology for treating pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Autonomix’s technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension, and chronic pain management, across a wide disease spectrum. The technology, however, is investigational and has not yet been cleared for U.S. marketing.